January 2024 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Betamethasone valerate lotion is more effective for treating multiple patchy alopecia areata.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
36 citations
,
October 2007 in “Journal of Investigative Dermatology” Betacellulin helps blood vessel growth in wounds but delays hair growth.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
March 2025 in “SKIN The Journal of Cutaneous Medicine” September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
September 2021 in “Han'gug mi'saengmul saengmyeong gong haghoeji/Han-guk misaengmul saengmyeong gonghak hoeji” Tetrathelmis tetrathele extract may help prevent hair loss and improve scalp health.
January 2023 in “Dermatologìâ ta venerologìâ” Biotin tablets and shampoo effectively stop hair loss and restore hair function in women.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
September 2010 in “Reactions weekly” The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”